EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Menin inhibitors as targeted therapy in KMT2A-Rearranged acute leukemia: A comprehensive review of current advances and therapeutic implications

Nazeer Ahmed, Shahroz Ali, Minahil Laraib Asif, Fatima Aslam, Meer Murtaza, Muhammad Ahsan, Kamil Ahmad Kamil, Asif Khaliq

Medical Oncology · 2025

DOI: 10.1007/s12032-025-03124-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Oncology, 2025. Verfasst von Nazeer Ahmed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Karachi Medical and Dental College, Karachi, Sindh, Pakistan. Hauptthemen laut MEDLINE: Myeloid-Lymphoid Leukemia Protein, Histone-Lysine N-Methyltransferase, Proto-Oncogene Proteins, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 84 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute leukemias harboring KMT2A rearrangements (KMT2A-r) or NPM1 mutations (NPM1-m) are aggressive subtypes with limited therapeutic options and high relapse rates. Their biology is sustained by aberrant HOXA9/MEIS1 transcription, critically dependent on the interaction between menin and the KMT2A complex. This insight has established menin as a tractable therapeutic target, leading to the development of selective small-molecule inhibitors. By disrupting the menin KMT2A interaction, these agents collapse leukemogenic transcriptional programs and promote blast differentiation. Among them, revumenib and ziftomenib have advanced furthest in clinical testing. Early-phase trials demonstrated meaningful responses in relapsed or refractory KMT2A-r and NPM1-m leukemias, and the recent FDA approval of revumenib represents the first clinical validation of menin inhibition in genetically defined disease. Nonetheless, resistance most often mediated by MEN1 pocket mutations limits durability, while treatment requires vigilance for differentiation syndrome and QTc prolongation. Ongoing trials are now evaluating menin inhibitors in rational combinations, frontline regimens, and maintenance therapy. Collectively, these advances highlight menin inhibition as a transformative strategy in acute leukemia, reshaping therapy through precision-targeted epigenetic intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid-Lymphoid Leukemia ProteinHistone-Lysine N-MethyltransferaseProto-Oncogene ProteinsLeukemia, Myeloid, AcuteLeukemiaAntineoplastic AgentsHumansNucleophosminGene RearrangementMolecular Targeted Therapy

Stichwörter der Autor:innen

Acute lymphoblastic leukemia (ALL)Acute myeloid leukemia (AML)Clinical trialsEpigenetic therapyKMT2A-rearranged leukemiaMLL-rearranged LeukemiaMenin inhibitorsMenin-KMT2A interactionReumenibTargeted therapy

Substanzen

Myeloid-Lymphoid Leukemia ProteinKMT2A protein, humanHistone-Lysine N-MethyltransferaseProto-Oncogene ProteinsMEN1 protein, humanNucleophosminNPM1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medicine, Karachi Medical and Dental College, Karachi, Sindh, Pakistan.
  • Department of Internal Medicine, Karachi Medical and Dental College, Karachi, Pakistan.
  • Institute of Cancer Therapeutics, University of Bradford, Bradford, UK.
  • Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.
  • Department of Oral and Maxillofacial Surgery , Karachi Medical and Dental College , Karachi, Pakistan.
  • Internal Medicine Department , Mirwais Regional Hospital , Kandahar, Afghanistan. drkamilahmad1@gmail.com.

Zitieren

APA

Ahmed, N., Ali, S., Asif, M. L., Aslam, F., Murtaza, M., Ahsan, M., Kamil, K. A., & Khaliq, A. (2025). Menin inhibitors as targeted therapy in KMT2A-Rearranged acute leukemia: A comprehensive review of current advances and therapeutic implications. Medical Oncology. https://doi.org/10.1007/s12032-025-03124-2

Vancouver

Ahmed N, Ali S, Asif ML, Aslam F, Murtaza M, Ahsan M, et al. Menin inhibitors as targeted therapy in KMT2A-Rearranged acute leukemia: A comprehensive review of current advances and therapeutic implications. Medical Oncology. 2025. doi:10.1007/s12032-025-03124-2

BibTeX
@article{Ahmed2025,
  author = {Ahmed, Nazeer and Ali, Shahroz and Asif, Minahil Laraib and Aslam, Fatima and Murtaza, Meer and Ahsan, Muhammad and Kamil, Kamil Ahmad and Khaliq, Asif},
  title = {Menin inhibitors as targeted therapy in KMT2A-Rearranged acute leukemia: A comprehensive review of current advances and therapeutic implications},
  journal = {Medical Oncology},
  year = {2025},
  doi = {10.1007/s12032-025-03124-2}
}
Kostenlos starten →